Fulltext

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Schadendorf, D. ; Amonkar, M. M. ; Milhem, M. ; Grotzinger, K. ; Demidov, L. V. ; Rutkowski, P. ; Garbe, C. ; Dummer, R. ; Hassel, J. C. ; Wolter, P. ; Mohr, P. ; Trefzer, U. ; Lefeuvre-Plesse, C. ; Rutten, A. ; Steven, N. ; Ullenhag, G. ; Sherman, L. ; Wu, F. S. ; Patel, K. ; Casey, M. ; Robert, C.

In: Annals of Oncology, 2014, vol. 25, no. 3, p. 700-706

Ajouter à la liste personnelle
    Titre
    • Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
    Auteur
    • Schadendorf, D.. Department of Dermatology, University Hospital Essen, Essen, Germany
    • Amonkar, M. M.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Milhem, M.. Department of Internal Medicine, University of Iowa Hospital and Clinics, Iowa City, USA
    • Grotzinger, K.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Demidov, L. V.. Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
    • Rutkowski, P.. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Garbe, C.. Department of Dermatology, University Hospital Tübingen, Tübingen, Germany
    • Dummer, R.. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    • Hassel, J. C.. Department of Dermatology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
    • Wolter, P.. Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals, Leuven Cancer Institute, Leuven, Belgium
    • Mohr, P.. Department of Dermato-Oncology, Elbekliniken, Buxtehude
    • Trefzer, U.. Department of Dermatology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • Lefeuvre-Plesse, C.. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
    • Rutten, A.. Department of Oncology, Sint-Augustinus, Wilrijk, Belgium
    • Steven, N.. The Wellcome Trust Clinical Research Facility, The Queen Elizabeth Hospital, Birmingham, UK
    • Ullenhag, G.. Department of Oncology, Uppsala University, Uppsala, Sweden
    • Sherman, L.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Wu, F. S.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Patel, K.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Casey, M.. Global Health Outcomes, Oncology Research and Development, and Clinical Statistics, GlaxoSmithKline, Collegeville
    • Robert, C.. Department of Dermatology and U 981, Institut Gustave Roussy, Villejuif-Paris-Sud, France
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2014, vol. 25, no. 3, p. 700-706. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:298888
    Summary
    We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib